MARKET

RGLS

RGLS

Regulus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7497
+0.0197
+2.70%
Closed 16:00 02/27 EST
OPEN
0.7300
PREV CLOSE
0.7300
HIGH
0.7880
LOW
0.6800
VOLUME
174.34K
TURNOVER
--
52 WEEK HIGH
1.740
52 WEEK LOW
0.5000
MARKET CAP
15.69M
P/E (TTM)
-0.4060
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RGLS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RGLS stock price target is 1.500 with a high estimate of 2.000 and a low estimate of 1.000.

EPS

RGLS News

More
  • Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
  • PR Newswire · 02/13 21:30
  • Penny Stocks to Buy Using Technical Analysis for February 2020
  • Investopedia · 01/31 21:58
  • How Regulus Therapeutics Inc. (NASDAQ:RGLS) Can Impact Your Portfolio Volatility
  • Simply Wall St. · 01/21 12:47
  • The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
  • Benzinga · 01/10 12:13

Industry

Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.52%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About RGLS

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
More

Webull offers kinds of Regulus Therapeutics Inc stock information, including NASDAQ:RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions.